Sernova Biotherapeutics
19
MENTIONS
5
EPISODES
3
PODCASTS
Search complete. 19 mentions across 5 episodes found for "Sernova Biotherapeutics".
Oct 15, 2026
Ginger VieiraHOST
It's...
Ginger VieiraHOST
I mean, I was just on a podcast interview the other day with Jonathan Rigby, the CEO of Sernova, and he was telling a story about how he actually blacked out on the sidewalk while he was walking his dog with his wife because his CGM, which wasn't the Eversense, didn't say he was low.
Ginger VieiraHOST
It said he was fine at, like, 104, and he wasn't fine, and his blood sugar crashed without him even knowing because the accuracy of other CGMs is so unreliable.
Ginger VieiraHOST
And I can't stress enough the consistency of the accuracy in the Eversense.
Stacey SimmsHOST
That is really the key.
Stacey SimmsHOST
My guests are Jonathan Rigby, president and CEO of Sernova.
Stacey SimmsHOST
He has lived with type 1 diabetes for most of his life.
Stacey SimmsHOST
And Will Rust, he's the president and CEO of Seraxis.
Jonathan RigbyGUEST
And, uh, what we are working on is we are looking to fix the whole thing and essentially give people a, a new pancreas.
Ginger VieiraHOST
Okay, so let's talk about Sernova.
Ginger VieiraHOST
So the first time I ever wrote about Sernova was probably 10 years ago when you were developing the pouch.
Ginger VieiraHOST
Can you talk about what was happening then and where you're at now? Which I know is a lot.
Ginger VieiraHOST
That's a big question.
20 MINS LATER
Ginger VieiraHOST
When two companies merge, it's not an acquisition, you're merging, you have two CEOs, who's in charge once you become BetaNova? [laughs]
Jonathan RigbyGUEST
[laughs] So, um, so Will, who you interviewed recently, uh, Will is the CEO of Siraxis.
Jonathan RigbyGUEST
I am the CEO of Sernova.
Erin HarrisHOST
T1D has seen tremendous advancement in glucose monitoring and insulin delivery, but replacing the insulin-producing cells that are lost remains a major challenge.
Erin HarrisHOST
And that's why the news that Sernova and Siraxis coming together to form BetaNova Biotherapeutics is particularly interesting for the cell and gene therapy field.
Erin HarrisHOST
The two companies together are combining Sernova's implantable and retrievable cell pouch technology with Siraxis' stem cell-derived pancreatic islet cells, with that ultimate goal of developing a functional cell replacement therapy for people living with T1D.
Erin HarrisHOST
To talk through all this with me, I sat down with Jonathan Rigby, he is the president and CEO of Sernova and proposed CEO of BetaNova, and Will Rust, PhD.
Erin HarrisHOST
He is the president and CEO of Siraxis and proposed president and chief scientific officer of BetaNova.
Erin HarrisHOST
Jonathan brings decades of biotech leadership experience, and he has worked across a number of companies developing therapies for serious diseases, and he has a really personal connection to type 1 diabetes.
Jonathan RigbyGUEST
Good morning, and, uh, thank you for, for having us.
Erin HarrisHOST
Absolutely.
Ginger VieiraHOST
Okay.
Ginger VieiraHOST
So that brings us to Sernova's pouch.
Ginger VieiraHOST
Is that what they're going to do for SerX's cells?
Will RustGUEST
Uh, yeah.
Will RustGUEST
That's the goal.
Will RustGUEST
So we have to have that safety net that I was talking about.
Will RustGUEST
So here's the thing about the ps- the, the cell pouch from Sernova.
Will RustGUEST
They did a 12-patient study with keratoveric islets, right? And two things were shown.